Clinical Trials Browser

Phase 2 × Sarcoma, Ewing × Docetaxel × Clear all

NCT02511132 2022-12-22

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Phase 2 Completed

22 enrolled 13 charts

Sarcoma, Sarcoma, Ewing